Kevin Ferguson, MD
Psychiatry · Chattanooga, TNNPI 1164530036
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Idorsia Pharmaceuticals US Inc at 41.0% of the total. Reporting peaked in 2023 at $17,766 and has fallen 77.8% since, to $3,941 in 2025. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 905 payments — averaging $48.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$18K
- AbbVie$8K
- Otsuka America Pharmaceutical, Inc.$3K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Supernus Pharmaceuticals, Inc.$1K
- plus $10K from 26 others
What the payments were for
- Consulting fees$5031%
- Speaking & faculty fees$22,84052%
- Travel & lodging$1,2493%
- Food & beverage$19,01844%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 43 | $17,904 |
| AbbVie(2 entities) | 74 | $7,926 |
| Otsuka America Pharmaceutical, Inc. | 125 | $2,886 |
| Neurocrine Biosciences, Inc. | 101 | $2,468 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 56 | $1,326 |
| Supernus Pharmaceuticals, Inc. | 45 | $1,283 |
| Alkermes, Inc. | 42 | $1,122 |
| Corium, LLC | 45 | $1,014 |
| Axsome Therapeutics, Inc. | 22 | $948 |
| Johnson & Johnson | 47 | $893 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $871 |
| Vanda Pharmaceuticals Inc. | 23 | $760 |
| Lundbeck LLC | 37 | $711 |
| Sunovion Pharmaceuticals Inc. | 36 | $698 |
| Teva Pharmaceuticals USA, Inc. | 39 | $663 |
| Eisai Inc. | 15 | $339 |
| Almatica Pharma LLC | 19 | $314 |
| Ironshore Pharmaceuticals Inc. | 17 | $299 |
| E.r. Squibb & Sons, L.L.C. | 7 | $244 |
| Neos Therapeutics, LP | 12 | $214 |
| Jazz Pharmaceuticals Inc. | 9 | $167 |
| Tris Pharma Inc | 7 | $119 |
| Collegium Pharmaceutical, Inc. | 5 | $110 |
| Shire North American Group Inc | 6 | $84 |
| Bausch Health US, LLC | 5 | $79 |
| Adlon Therapeutics L.p. | 4 | $60 |
| Merck | 4 | $58 |
| Avanir Pharmaceuticals, Inc. | 2 | $56 |
| Noven Therapeutics, LLC | 1 | $24 |
| Rhodes Pharmaceuticals L.p. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $16 |
| Neuronetics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,682 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 36 | $295,828 |
| VraylarCariprazine Hcl | 77 | $119,278 |
| TrintellixVortioxetine Hydrobromide | 79 | $59,801 |
| CaplytaLumateperone Tosylate | 21 | $35,035 |
| AuvelityDextromethorphan Hbr/Bupropion | 27 | $31,552 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 665 | $24,408 |
| FetzimaLevomilnacipran Hcl | 17 | $20,151 |
| BelsomraSuvorexant | 43 | $18,197 |
| Aripiprazole | 405 | $18,101 |
| SaphrisAsenapine Maleate | 12 | $17,382 |
| QuviviqDaridorexant Hcl | 36 | $17,150 |
| Oxcarbazepine | 239 | $15,836 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 127 | $13,864 |
| Bupropion XlBupropion Hcl | 494 | $12,867 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $12,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,468 | $295,82836 claims |
| AbbVieVraylar, Fetzima, Saphris | $7,926 | $156,812106 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $871 | $72,48599 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,326 | $35,03521 claims |
| Axsome Therapeutics, Inc.Auvelity | $948 | $31,55227 claims |
| MerckBelsomra | $58 | $18,19743 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $17,904 | $17,15036 claims |
| Eisai Inc.Dayvigo | $339 | $8,60224 claims |
| Shire North American Group IncMydayis | $84 | $3,48712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Chattanooga
- Oliver GregoryChattanooga$13K
- Richard MauronerChattanooga$7K
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Sricharan MoturiFranklin$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.